Next Article in Journal
Immunogenicity of Innovative and Biosimilar Monoclonal Antibodies
Next Article in Special Issue
Kinetic Analysis and Epitope Mapping of Monoclonal Antibodies to Salmonella Typhimurium Flagellin Using a Surface Plasmon Resonance Biosensor
Previous Article in Journal
IgE Antibodies: From Structure to Function and Clinical Translation
Article Menu

Export Article

Open AccessArticle

Evaluation of the NovaLisa™ Leishmania Infantum IgG ELISA in A Reference Diagnostic Laboratory in A Non-Endemic Country

1
Department of Bacteria, Parasites & Fungi, Statens Serum Institut, Artillerivej 5, DK–2300 Copenhagen S, Denmark
2
Department of Biochemistry and Microbiology, Faculty of Biological and Agronomic Sciences, Mouloud Mammeri University of Tizi Ouzou, 15000 Tizi Ouzou, Algeria
3
Department of Natural and Life Sciences, Faculty of Exact Sciences and Natural and Life Sciences, Mohamed Khider University of Biskra, 07000 Biskra, Algeria
*
Author to whom correspondence should be addressed.
Antibodies 2019, 8(1), 20; https://doi.org/10.3390/antib8010020
Received: 7 February 2019 / Revised: 22 February 2019 / Accepted: 23 February 2019 / Published: 27 February 2019
(This article belongs to the Special Issue Antibody-Based Diagnostics)
  |  
PDF [213 KB, uploaded 27 February 2019]

Abstract

Anti-Leishmania antibodies may be detectable in patients with leishmaniasis. Here, we compared a commercial enzyme-linked immunosorbent assay (ELISA) for the detection of anti-Leishmania antibodies, with an immunofluorescence antibody test (IFAT) that is no longer commercially available. Eighty-six serum samples from 73 patients were tested. The results obtained by the NovaLisa™ Leishmania infantum IgG ELISA, interpreted according to the instructions of the manufacturer, but with a modified cut-off for borderline positive values, were compared with the IFAT results that were already available. Moreover, Leishmania Western blot IgG results were available for 43 of the samples. The overall concordance of ELISA and IFAT was 67%. The ELISA and IFAT tests scored as 24% and 15% of the samples being positive, respectively, while 13% and 33% scored as borderline-positive, respectively. Using a Western blot (WB) as the reference, the sensitivities and specificities for the positive plus borderline-positive samples combined was 95.5% (95% confidence interval (CI), 77.2–99.9%) and 81.0% (95% CI, 58.1–94.6%) for ELISA, and 95.5% (95% CI, 77.2–99.9%) and 42.9% (95% CI, 21.8–66.0%) for IFAT, respectively. Overall, the ELISA proved to be a cost-effective alternative to the IFAT, due to its higher accuracy and specificity, and with a consequently lower number of confirmatory WB tests being required. Lastly, we also present data on the associations between seroconversion and the type of leishmaniasis. View Full-Text
Keywords: parasite; clinical microbiology; vector-borne disease; leishmaniasis; diagnosis; diagnostic methods; molecular epidemiology parasite; clinical microbiology; vector-borne disease; leishmaniasis; diagnosis; diagnostic methods; molecular epidemiology
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Supplementary material

SciFeed

Share & Cite This Article

MDPI and ACS Style

Stensvold, C.R.; Høst, A.V.; Belkessa, S.; Nielsen, H.V. Evaluation of the NovaLisa™ Leishmania Infantum IgG ELISA in A Reference Diagnostic Laboratory in A Non-Endemic Country. Antibodies 2019, 8, 20.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Antibodies EISSN 2073-4468 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top